Industry Update: The latest developments in therapeutic delivery

ISSN： 2041-5990

Source： Therapeutic Delivery, Vol.4, Iss.12, 2013-12, pp. : 1487-1492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The present industry update covers the period September 2013, with information sourced predominantly from company press releases, regulatory and patent agencies. This month saw approvals for a number of products employing drug–delivery technologies including Purdue’s new 15 mcg/h dosage strength of Butrans^® and Medtronics first generation artificial pancreas device system with Threshold Suspend automation. The first European approval was also achieved for a biosimilar monoclonal antibody product, Hospira’s Inflectra™ (infliximab). Delcath, however, were unsuccessful with their new drug application for Melblez™ for the treatment of patients with unresectable ocular melanoma metastatic to the liver. Several notable collaborations were announced this month including the expansion of an agreement between Jade Pharmaceuticals and BioTime for the use of the HyStem^® hydrogel technology for the ocular delivery and Activero and Chiesi agreeing to collaborate on a novel drug device combination in the treatment of cystic fibrosis. CeQur successfully raised finance to support the commercialization of its wearable insulin device that seeks to provide 3 days of consistent insulin delivery and Catalent have announced the expansion of their hot melt extrusion capabilities that may offer delivery options for therapeutics with solubility issues.